Guggenheim raises Ideaya Biosciences stock price target on DLL3 data

Guggenheim raised Ideaya Biosciences' price target to $57 from $54 and reiterated a Buy rating, citing favorable risk-reward at about $39 per share, with modeled upside to $48 and downside to $30 ahead of IDE849 data in 2H 2026. The firm estimates IDE849 could generate peak U.S. revenue of $690 million on an adjusted basis, or $2.2 billion unadjusted, and views the planned Phase 3 study in second-line-plus extensive-stage SCLC as having a high probability of success. Ideaya also raised approximately $345 million in gross proceeds through a public offering to fund R&D and initiated a Phase 1 trial of IDE892 plus IDE397 in MTAP-deleted solid tumors.

Analysis

IDYA is transitioning from a platform-value biotech to a single-asset, clinical-proof valuation: the stock’s next meaningful repricing will be driven less by sell-side target revisions and more by whether IDE849 demonstrates a therapeutic index that differentiates it from the expanding DLL3 field. The key competitive benchmark is not merely response rate; durability, discontinuation rates, and hematologic toxicity will determine whether IDE849 can displace or complement Amgen’s tarlatamab (AMGN) and other DLL3-directed programs. A clean efficacy signal without compelling safety would likely support only a modest multiple expansion because ADC development history shows that dose optimization can materially delay registrational timelines.

The recent financing removes near-term solvency risk but creates an important overhang: the market must now underwrite a substantially larger diluted share base against revenues that remain several years away. This makes the setup asymmetric around clinical data rather than around cash runway. Over the next 1-3 months, catalyst anticipation can support the shares, but 6-18 month returns depend on confirmation that IDE849’s dose intensity and durability justify a differentiated commercial model; otherwise, IDYA risks rerating toward cash-adjusted pipeline value despite a healthy balance sheet.

Consensus appears to be assigning a high probability to a registrational path before global data establish reproducibility outside early China cohorts. Cross-regional consistency matters because small-cell lung cancer populations, prior-treatment mix, and site-level adverse-event reporting can materially alter apparent activity. The most investable second-order read-through may be negative: weak IDE849 safety or durability would reinforce the view that DLL3 is more suited to bispecific approaches than TOP1i ADCs, benefiting AMGN competitively while pressuring other early DLL3 ADC developers.

The article’s timing references should be independently verified before trading, particularly the precise ESMO presentation slot, dataset cutoff, patient disposition, and fully diluted share count. These inputs determine whether an upcoming event is genuinely incremental or largely previewed, and whether the current valuation already embeds a positive readout.

Key Decisions for Investors

• Maintain IDYA as a watch-list long rather than initiate a full position ahead of data; enter only after confirming the event date and reviewing the abstract for efficacy durability, grade 3+ cytopenias, treatment discontinuations, and prior DLL3 exposure. A post-data starter position is justified only if safety is clearly differentiated and the stock does not gap more than approximately 20% on the release.
• For event-driven exposure, use a defined-risk IDYA call spread dated at least 1-2 months beyond the confirmed data event rather than common equity. Size premium at risk to the probability of an early-phase binary miss; the thesis is falsified by weak durability, meaningful dose reductions, or global results that fail to replicate the earlier cohort.
• Consider a relative-value expression long AMGN versus short a basket of pre-commercial oncology beta only if IDE849 data disappoint. AMGN has existing DLL3 commercialization optionality and is less exposed to single-study execution risk; cover the pair if IDYA demonstrates durable activity with a materially cleaner safety profile than competing DLL3 approaches.
• Do not anchor on published price targets. Recalculate IDYA’s enterprise value using the latest fully diluted share count, net cash after expected operating burn, and probability-adjusted peak sales; if the implied valuation already assumes a high probability of registrational success, reduce or avoid pre-data exposure.